TrialNature medicine2022

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.

Thomas Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.